Genky DrugStores Co., Ltd. (9267) AI Stock Analysis

• Market Cap: ¥148.88B
• Dividend Yield: 0.25%
• Average Volume (3M): 62.69K
• Price to Earnings (P/E): 20.9
• Beta (1Y): 0.18
• Revenue Growth: 9.97%
• EPS Growth: 16.27%
• Country: JP
• Employees: 1,661
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 67.01
• Shares Outstanding: 30,996,967
• 10 Day Avg. Volume: 60,060
• 30 Day Avg. Volume: 62,690
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: ¥6,024.00 ▲(17.43% Upside)

Genky DrugStores Co., Ltd. shows strong financial performance with consistent revenue growth and profitability, which is the most significant factor in the overall score. The technical analysis indicates a bullish trend, supporting the positive outlook. However, the valuation is only fair, with a low dividend yield, which slightly tempers the overall score.

Genky DrugStores Co., Ltd. Business Overview & Revenue Model

Company Description

Genky DrugStores Co., Ltd. operates a chain of drug stores. The company was founded in 1988 and is headquartered in Sakai, Japan.

How the Company Makes Money

Genky DrugStores generates revenue primarily through the sale of a diverse array of products in its drugstores, which include prescription medications, over-the-counter drugs, personal care items, and groceries. The company's revenue model is built on high sales volume, driven by its extensive store network and strategic location choices that cater to consumer convenience. Key revenue streams include retail sales, which are bolstered by promotional campaigns, loyalty programs, and seasonal marketing strategies. Additionally, Genky may benefit from supplier partnerships, allowing for favorable purchasing terms and exclusive product offerings that enhance profit margins. The company's focus on expanding its footprint through new store openings and optimizing existing locations also contributes significantly to its earnings.

Genky DrugStores Co., Ltd. Financial Statement Overview

Summary

Genky DrugStores Co., Ltd. demonstrates a strong financial position with consistent revenue growth and profitability. The balance sheet reflects a stable leverage position, while the income statement shows robust margins. However, the negative free cash flow highlights a need for improved cash management strategies.

Income Statement

Genky DrugStores Co., Ltd. has shown consistent revenue growth with a 4.51% increase in the latest year. The gross profit margin is healthy at approximately 20.36%, and the net profit margin has improved to 3.52%. EBIT and EBITDA margins are also stable, indicating strong operational efficiency. Overall, the income statement reflects a robust financial performance with positive growth trends.

Balance Sheet

The company's debt-to-equity ratio has improved over the years, currently at 0.64, indicating a balanced leverage position. The return on equity is strong at 13.55%, showcasing effective use of equity to generate profits. The equity ratio is stable, suggesting a solid financial structure. However, the company should continue monitoring its debt levels to maintain financial stability.

Cash Flow

Operating cash flow remains strong, but the free cash flow has turned negative, indicating potential challenges in cash generation after capital expenditures. The operating cash flow to net income ratio is healthy, but the negative free cash flow growth rate of -191.53% is a concern. The company needs to address its cash flow management to ensure long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	195.66B	200.79B	184.86B	169.06B	154.64B	142.38B
Gross Profit	39.76B	40.89B	37.62B	34.55B	30.95B	30.29B
EBITDA	15.45B	16.41B	14.47B	11.73B	10.73B	10.78B
Net Income	6.74B	7.07B	6.32B	4.76B	4.42B	4.83B
Balance Sheet
Total Assets	127.25B	127.33B	113.94B	105.91B	97.12B	90.80B
Cash, Cash Equivalents and Short-Term Investments	12.03B	6.22B	5.90B	5.33B	5.44B	7.91B
Total Debt	34.54B	34.37B	30.65B	32.35B	30.96B	28.56B
Total Liabilities	76.03B	73.89B	67.26B	65.23B	60.88B	58.63B
Stockholders Equity	51.21B	53.43B	46.68B	40.68B	36.23B	32.17B
Cash Flow
Free Cash Flow	0.00	-2.50B	2.81B	-1.16B	-4.43B	3.12B
Operating Cash Flow	0.00	12.60B	13.26B	8.77B	6.08B	12.08B
Investing Cash Flow	0.00	-15.62B	-10.63B	-9.74B	-10.59B	-8.83B
Financing Cash Flow	0.00	3.35B	-2.06B	854.00M	2.04B	-1.95B

Genky DrugStores Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5130.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Positive. The current price of 5130 is above the 20-day moving average (MA) of 4925.00, above the 50-day MA of 4845.60, and above the 200-day MA of 3798.83, indicating a bullish trend. The MACD of 59.35 indicates Negative momentum. The RSI at 56.59 is Neutral, neither overbought nor oversold. The STOCH value of 63.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9267.

Genky DrugStores Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9267	―	¥148.88B	20.86	―	0.25%	9.97%	16.27%
3141	―	¥607.56B	31.00	―	1.17%	7.79%	-13.09%
9989	―	$484.41B	15.24	12.18%	3.12%	6.64%	6.38%
3549	―	¥410.50B	22.78	―	0.36%	15.81%	27.05%
3391	―	$619.73B	27.82	―	10.97%	4.63%	-47.30%
7649	―	$659.47B	15.24	15.71%	1.05%	21.81%	67.76%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Genky DrugStores Co., Ltd. Corporate Events

Genky DrugStores Reports Strong Q3 Financial Performance

Genky DrugStores Co., Ltd. reported a strong financial performance for the three months ended September 20, 2025, with significant increases in net sales and income compared to the previous year. The company’s robust growth in operating and ordinary income reflects its solid market positioning and effective operational strategies, which are expected to continue supporting its financial stability and stakeholder confidence.

The most recent analyst rating on (JP:9267) stock is a Buy with a Yen5046.00 price target. To see the full list of analyst forecasts on Genky DrugStores Co., Ltd. stock, see the JP:9267 Stock Forecast page.

Genky DrugStores Completes Treasury Stock Disposal for Compensation

Genky DrugStores Co., Ltd. has completed the payment procedure for the disposal of 69,000 shares of its treasury stock as restricted stock compensation. This move involves a total transaction amount of 336,030,000 Yen, with shares allocated to directors and subsidiary employees, potentially impacting the company’s financial structure and stakeholder interests.

The most recent analyst rating on (JP:9267) stock is a Buy with a Yen5046.00 price target. To see the full list of analyst forecasts on Genky DrugStores Co., Ltd. stock, see the JP:9267 Stock Forecast page.

Genky DrugStores Implements Restricted Stock Compensation Plan

Genky DrugStores Co., Ltd. has announced a resolution to dispose of its treasury stock as part of a restricted stock compensation plan aimed at incentivizing its directors and officers to enhance corporate value. This plan involves the issuance or disposal of 69,000 shares to eligible directors and employees, with a focus on aligning their interests with those of shareholders and ensuring long-term value creation.

The most recent analyst rating on (JP:9267) stock is a Buy with a Yen5046.00 price target. To see the full list of analyst forecasts on Genky DrugStores Co., Ltd. stock, see the JP:9267 Stock Forecast page.

Genky DrugStores Introduces Restricted Stock Compensation Plan

Genky DrugStores Co., Ltd. announced the introduction of a restricted stock compensation plan aimed at incentivizing its directors to enhance corporate value and align their interests with shareholders. This system, which will be proposed at the upcoming Annual General Meeting, involves granting monetary compensation claims to eligible directors for acquiring restricted stock, with a cap of 200 million yen per year and a limit of 100,000 shares. The plan is designed to strengthen the company’s operational strategy and potentially improve its market positioning by fostering greater alignment between directors and shareholders.